UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
Trump warns Iran not to retaliate after Ayatollah Ali Khamenei is killed
The Iranian government has announced 40 days of mourning. The country's supreme leader was killed following an attack launched by the U.S. and Israel on Saturday against Iran.
Iran fires missiles at Israel and Gulf states after U.S.-Israeli strike kills Khamenei
Iran fired missiles at targets in Israel and Gulf Arab states Sunday after vowing massive retaliation for the killing of Supreme Leader Ayatollah Ali Khamenei by the United States and Israel.
House Dem. Leader Jeffries responds to air strikes on Iran by U.S. and Israel
NPR's Emily Kwong speaks to House Minority Leader Hakeem Jeffries (D-NY), who is still calling for a vote on a war powers resolution following a wave of U.S.- and Israel-led airstrikes on Iran.
Iran’s Ayatollah Ali Khamenei is killed in Israeli strike, ending 36-year iron rule
Khamenei, the Islamic Republic's second supreme leader, has been killed. He had held power since 1989, guiding Iran through difficult times — and overseeing the violent suppression of dissent.
Found: The 19th century silent film that first captured a robot attack
A newly rediscovered 1897 short by famed French filmmaker Georges Méliès is being hailed as the first-ever depiction of a robot in cinema.
‘One year of failure.’ The Lancet slams RFK Jr.’s first year as health chief
In a scathing review, the top US medical journal's editorial board warned that the "destruction that Kennedy has wrought in 1 in office might take generations to repair."
